Silence-Logo-FINAL-rgb.png
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
October 15, 2021 07:05 ET | Silence Therapeutics plc
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform
October 15, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform Hansoh will make a $16 million upfront cash payment and Silence has the...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics to Host R&D Day on October 21, 2021
October 07, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference
September 28, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference 28 September 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development
September 01, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development 1 September 2021 LONDON, Silence Therapeutics plc,...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics to Participate in September Investor Conferences
August 25, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics to Participate in September Investor Conferences 25 August 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Capture.PNG
Silence Therapeutics Reports Half-Year 2021 Results
August 12, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a)Silence to...
Capture.PNG
Notice of half year results
July 15, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Notice of Half Year Results 15 July 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and...
Capture.PNG
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
May 25, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration Companies on-track to initiate work on five targets within the first...
Capture.PNG
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
May 19, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers Data showed SLN124, an siRNA which targets TMPRSS6, was safe and effective in reducing plasma...